Project Grant R01AI195020
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$862K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This $128,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of novel chimeric antigen receptor (CAR) T cell therapies to eliminate HIV reservoirs in non-human primate models. The goal is to engineer a second-generation anti-PD-1 CAR T cell therapy that can more specifically and safely deplete the pool of HIV-infected T follicular helper (Tfh) cells, which...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on enhancing the persistence of CD4CAR T-cell therapies to treat HIV infection. The $186,408 award will support research to characterize and overcome the inhibitory effects of soluble HIV antigen on CD4CAR T-cell function, as well as strategies to extend the persistence of these therapeutic T cells using the IL15...
This Project Grant award of $3,643,653 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program supports a consortium of researchers at the University of Pennsylvania to develop a chimeric antigen receptor (CAR) T-cell approach for controlling HIV replication and eliminating the viral reservoir. The key elements of the program include: 1) engineering HIV-specific T-cells with improved function and persistence,...
This Project Grant award of $343,744 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of a comprehensive strategy for an Investigational New Drug (IND) submission and clinical development of a hematopoietic stem/progenitor cell-based chimeric antigen receptor (CAR) gene therapy to functionally cure HIV infection. The key products and services to be delivered include: 1) Formulating a strategic plan...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $220,000 to the Fred Hutchinson Cancer Center to conduct research on natural killer (NK) cell memory responses to HIV. The key objectives are to use a novel lineage tracing method called ASAP-seq to identify and characterize long-lived, HIV-specific NK memory cell clones in a unique longitudinal cohort of...
This Project Grant award of $1,657,972 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to characterize allogeneic T cell responses that may mediate a functional cure for HIV. The research, conducted by Oregon Health & Science University (OHSU), aims to define the allogeneic T cell responses and their targets in individuals cured of HIV after allogeneic hematopoietic stem cell...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel HIV cure strategy by targeting CD127-expressing tissue reservoir cells. The total funding amount is $250,791.00, with an award date of August 6, 2024 and an ultimate completion date of July 31, 2026. The key products and services to be delivered under this grant include: Utilizing an ex vivo...
This Project Grant award of $857,346 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by the Fred Hutchinson Cancer Center to study metabolite- and cytokine-mediated signals that control human CD8 T cell responses in tissues. The research aims to define the balance of activating and inhibitory signals present in healthy and acutely infected human tissues, which is relevant to understanding immune...
This Project Grant award for $1,314,572.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at developing a cure strategy for HIV-1 using CD4-mimetic compounds (CD4MCs) and CD4-induced antibodies (CD4I Abs). The research, conducted by Yale University, leverages the recent discovery of a new class of indoline CD4MCs that display improved antiviral potency and breadth...